Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9903641 | 0.80 | CYP1A2 (0.48) | CYP1A2GRM5FFAR1NPC1RAB9A | |
| SCHEMBL1992055 | 0.73 | APP (0.46) | CYP1A2GRM5FFAR1NPC1RAB9A | |
| SCHEMBL27881974 | 0.71 | FFAR1 (0.58) | CYP1A2GRM5FFAR1NPC1RAB9A | |
| SCHEMBL9903316 | 0.70 | GRM5 (0.43) | GRM5FFAR1DRD2DRD4DRD3 | |
| SCHEMBL3346711 | 0.69 | GRM5 (0.52) | CYP1A2GRM5FFAR1NPC1RAB9A | |
| SCHEMBL25334458 | 0.68 | SLC6A2 (0.35) | DRD2DRD4DRD3SLC6A2SLC6A4 | |
| SCHEMBL1930369 | 0.67 | NPC1 (0.51) | CYP1A2GRM5FFAR1NPC1RAB9A | |
| SCHEMBL25417020 | 0.67 | KDR (0.43) | CYP1A2GRM5DRD2DRD4DRD3 | |
| SCHEMBL13520581 | 0.66 | FFAR1 (0.52) | CYP1A2GRM5FFAR1NPC1RAB9A | |
| SCHEMBL28848483 | 0.66 | GRM5 (0.56) | CYP1A2GRM5FFAR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-07-12 | — | — | US | claimed |
| EP-2462142-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-06-13 | — | — | EP | claimed |
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-07-12 | — | — | US | disclosed |
| EP-2462142-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | GRM5, GRIK5, GRM1 | CYP1A2 3627/4885GRM5 1/4885FFAR1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.